Is there a reproductive safety risk in male patients treated with acitretin (neotigason/soriatane?
Review of preclinical data including genotoxicity assays and a male rat reproduction toxicology study demonstrates that acitretin (Neotigason)/Soriatane) does not affect the reproductive outcome in naive females mated with treated males. Prospective studies of teratogenic risk or impairment of fertility cannot be ethically conducted in humans. However, it is highly unlikely that any fetal malformation could be induced by an ejaculate containing traces of acitretin. Indeed, worldwide postmarketing surveillance has not revealed any cases of retinoid embryopathy associated with paternal treatment with acitretin. Birth defects seen in pregnancies fathered by male acitretin patients were all events expected to occur in the general population at known frequencies. In conclusion, therefore, available data do not appear to indicate any reproductive safety risk due to paternal treatment with acitretin.
Geiger
J-M
JM
Department of Clinical Research, F Hoffmann-La Roche Ltd., Basel, Switzerland. jean-marie.geiger@wanadoo.fr
Walker
M
M
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000022:Abortion, Spontaneous / Q000139:chemically induced; D017255:Acitretin / Q000009:adverse effects*; D000818:Animals; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000009:adverse effects*; D008297:Male; D018812:Paternal Exposure; D011247:Pregnancy
D007641:Keratolytic Agents; D017255:Acitretin